Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
NCT ID NCT07649395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at when to start giving a drug called rhTPO to cervical cancer patients whose platelet levels drop during chemoradiation. The goal was to see if starting treatment earlier could prevent severe low platelet counts. Researchers studied 75 patients and compared two different timing strategies. The findings could help doctors decide the best time to use rhTPO to avoid complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant human thrombopoietin (rhTPO)
- What this could lead to
- If successful, this could establish the best time to start rhTPO to prevent dangerously low platelet counts during cervical cancer treatment.
- What could go wrong
- This is a small, completed study with no phase designation, so results may not be definitive or widely applicable. The intervention only addresses a side effect, not the cancer itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 600000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can we predict who will benefit from immunotherapy? new study aims to find out.
- New drug cocktail targets Hard-to-Treat cancers
- Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
- New radioactive drug targets Hard-to-Treat cancers in early trial